ClinicalTrials.gg
CompletedNCT07420491Updated Feb 19, 2026

The Efficacy and Safety of Reconyl in Acute Cough Treatment

A Phase 3 interventional study of Reconyl and Placebo of Reconyl in Cough, sponsored by Dexa Medica Group. Completed at 1 site in Indonesia. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Dexa Medica Group · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2025, registered Feb 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a 2-arm, prospective, randomized, double-blind, parallel, controlled, non-inferiority study comparing Reconyl at a dose of 225 mg three times daily and Reconyl Placebo three times daily for a 7-day course of therapy.

Reconyl is a combination of four Indonesian herbals, Vitex trifolia folium, Zingiber officinale rhizome, Abrus precatorius folium, and Phaleria macrocarpa fructus, which have been traditionally used in treating cough and common cold. A combination of these herbals is expected to relieve cough and soothe throat, provide a promising cough treatment which has no side effects.

Read the detailed description

There will be 2 groups of treatment; each group will consist of 72 subjects with the treatment regimens for 7 days:

Treatment I : 1 tablet of Reconyl 225 mg three times daily; Treatment II : 1 tablet of Reconyl Placebo three times daily.

Subjects will be asked to come to the clinic at Baseline and at Visit 1 (Day 7) for evaluation of treatment efficacy. During the 7-day study period, subjects should record product consumption, any adverse events, and their daily VAS score in the provided Patient's Diary.

The safety profile of study medication other than vital signs and adverse event will be measured at Baseline and End of Study.

02

Conditions studied

  • Cough

Browse trials for

03

In context

Cough

429 studies on the registry are indexed under Cough; 69 are open to participants now.

This study's enrollment of 144 is above the median of 80 across 321 interventional studies indexed under Cough.

Browse Cough studies →

Lead sponsor

Dexa Medica Group is the lead sponsor of 44 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed from the subject or the subject's legally acceptable representatives (must obtained before any trial related activities)
  2. Male or female subjects, aged 18-50 years at screening
  3. Experience acute cough, defined as sudden onset dominant or main symptom of acute or worsened cough, with or without sputum, in the span of 72 hours, avoiding prescription and non-prescription cough-relieving medications (e.g. antitusives such as codeine-based cough supressants or dextromethorphan HBr, and mucolytics such as N-acetylsistein, Bromhexin and Ambroxol), within 24 hours before entering the study.
  4. The condition of the patient does not have any illness other than acute cough that could possibly interfere with the study evaluation, such as (COPD), suspect GERD, rhinitis, asthma, tuberculosis (TB), and pneumonia.
  5. Cooperative and able to fill out study material

Exclusion criteria

Exclusion Criteria:

  1. Subject with febrile within 24 hours before screening, or has body temperature ≥ 38°C during screening visit
  2. Personal/family history of allergy or or contradiction to any component of the drugs
  3. History or clinical evidence of according to investigator assessment, or currently under treatment with immunosuppressive agents
  4. Participation in any other trial less than 90 days before
  5. Pregnancy or lactation
  6. History of drug or alcohol abuse within 12 months prior to screening
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
144 participants (actual)

Study arms

  • Experimental
    Reconyl

    1 tablet of Reconyl 225 mg three times daily

    Drug: Reconyl

  • Placebo comparator
    Placebo of Reconyl

    1 tablet of Reconyl Placebo three times daily

    Drug: Placebo of Reconyl

Interventions

  • DrugReconyl

    Reconyl will be given 1 tablet three times daily as the Investigational Product.

    Also known as: Herbakof

  • DrugPlacebo of Reconyl

    Placebo of Reconyl will be given 1 tablet three times daily as the Placebo Comparator.

06

What researchers measure

Primary outcomes

  1. Changes of VAS Score on Cough

    Changes of VAS Score on Cough from Baseline to Day 7 of study treatment.

    Time frame: 7 days

Secondary outcomes

  1. Changes of LCQ-acute score on Cough

    Changes of LCQ-acute score on Cough from Baseline to Day 7 of study treatment.

    Time frame: 7 days

  2. Renal function (Serum creatinine and eGFR)

    Concentration of serum creatinine and eGFR at Baseline and at the End of study

    Time frame: 7 days

  3. Liver function (ALT and AST)

    Concentration of aspartate transaminase (AST) to alanine transaminase (ALT) at Baseline and at the End of study

    Time frame: 7 days

  4. Adverse events

    Adverse event, will be observed throughout the study conduct

    Time frame: 7 days

07

Study locations

1 site
  • Velia Medika Primary Care Clinic
    Jakarta, Jakarta Special Capital Region 12430, Indonesia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2025 to primary completion in Oct 2025, 3 months.

Of 18 phase 3 interventional studies under Cough, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 37. This study's 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Jun 26, 2025
Primary completionActual
Oct 3, 2025
CompletionActual
Oct 3, 2025
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07420491
Lead sponsor
Dexa Medica Group
Collaborators
PT Equilab International
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Jun 26, 2025
Primary completion
Oct 3, 2025
Completion
Oct 3, 2025
Last update
Feb 19, 2026

Study contacts

Jusuf Kristianto, MD, PhD
principal investigator · Velia Medika Primary Care Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion